Vertex Pharmaceuticals Incorporated (VRTX) : Cullinan Associates Inc scooped up 27,323 additional shares in Vertex Pharmaceuticals Incorporated during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 1, 2016. The investment management firm now holds a total of 128,010 shares of Vertex Pharmaceuticals Incorporated which is valued at $11,231,597.Vertex Pharmaceuticals Incorporated makes up approximately 0.91% of Cullinan Associates Inc’s portfolio.
Vertex Pharmaceuticals Incorporated opened for trading at $85.67 and hit $88.46 on the upside on Friday, eventually ending the session at $87.74, with a gain of 2.00% or 1.72 points. The heightened volatility saw the trading volume jump to 12,92,792 shares. Company has a market cap of $21,702 M.
On the company’s financial health, Vertex Pharmaceuticals Incorporated reported $0.09 EPS for the quarter, missing the analyst consensus estimate by $ -0.19 based on the information available during the earnings call on Apr 27, 2016. Analyst had a consensus of $0.28. The company had revenue of $398.10 million for the quarter, compared to analysts expectations of $438.21 million. The company’s revenue was up 187.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.62 EPS.
Many Wall Street Analysts have commented on Vertex Pharmaceuticals Incorporated. Shares were Reiterated by RBC Capital Mkts on Apr 28, 2016 to “Outperform” and Lowered the Price Target to $ 115 from a previous price target of $135 .Shares were Reiterated by Barclays on Apr 28, 2016 to “Overweight” and Lowered the Price Target to $ 110 from a previous price target of $135 .Vertex Pharmaceuticals Incorporated was Downgraded by Goldman to ” Neutral” on Apr 28, 2016.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor) Lumacaftor in combination with Ivacaftor VX-661 in combination with Ivacaftor VX-803 VX-970 and VX-222. The Companys product KALYDECO is available in the market.